Skip to main content

Blenoxane Disease Interactions

There are 3 disease interactions with Blenoxane (bleomycin).

Major

Bleomycin (applies to Blenoxane) pulmonary infiltrates/fibrosis

Major Potential Hazard, High plausibility. Applicable conditions: Pulmonary Impairment

Pulmonary pneumonitis occurs in 10% of patients during bleomycin therapy and 1% progress to pulmonary fibrosis and death. Although pulmonary toxicity is age and dose related, occurring primarily in patients over 70 years of age and in those receiving a total dose > 400 units, it has occurred in younger patients at a lower dose. Extreme caution should be exercised when administering bleomycin in patients with compromised pulmonary function. Patients should be instructed to immediately report symptoms of dyspnea, cough, or congestion. Close clinical monitoring of pulmonary function is recommended.

References

  1. Wolkowicz J, Sturgeon J, Rawji M, Chan CK "Bleomycin-induced pulmonary function abnormalities." Chest 101 (1992): 97-101
  2. Hartmann LC, Frytak S, Richardson RL, Coles DT, Cupps RE "Life-threatening bleomycin pulmonary toxicity with ultimate reversibility." Chest 98 (1990): 497-9
  3. Brown WG, Hasan FM, Barbee RA "Reversibility of severe bleomycin-induced pneumonitis." JAMA 239 (1978): 2012-4
  4. Bechard DE, Fairman RP, DeBlois GG, Via CT "Fatal pulmonary fibrosis from low-dose bleomycin therapy." South Med J 80 (1987): 646-9
  5. Jones AW "Bleomycin lung damage: the pathology and nature of the lesion." Br J Dis Chest 72 (1978): 321-6
  6. Doll DC "Fatal pneumothorax associated with bleomycin-induced pulmonary fibrosis." Cancer Chemother Pharmacol 17 (1986): 294-5
  7. Zucker PK, Khouri NF, Rosenshein NB "Bleomycin-induced pulmonary nodules: a variant of bleomycin pulmonary toxicity." Gynecol Oncol 28 (1987): 284-91
  8. Dalgleish AG, Woods RL, Levi JA "Bleomycin pulmonary toxicity: its relationship to renal dysfunction." Med Pediatr Oncol 12 (1984): 313-7
  9. "Product Information. Blenoxane (bleomycin)." Bristol-Myers Squibb PROD (2001):
View all 9 references
Major

Bleomycin (applies to Blenoxane) renal dysfunction

Major Potential Hazard, High plausibility.

Bleomycin is primarily eliminated by the kidney. Approximately 60% to 70% of bleomycin is excreted in the urine as active drug. Moderate renal failure reduces elimination to < 20% of the drug. Extreme caution should be exercised when administering bleomycin in patients with existing or predisposition to significantly compromised renal function. Close clinical monitoring of renal function is recommended.

References

  1. McLeod BF, Lawrence HJ, Smith DW, Vogt PJ, Gandara DR "Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency." Cancer 60 (1987): 2617-20
  2. Bennett WM, Pastore L, Houghton DC "Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure." Cancer Treat Rep 64 (1980): 921-4
  3. "Product Information. Blenoxane (bleomycin)." Bristol-Myers Squibb PROD (2001):
Moderate

Bleomycin- hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The effect of hepatic insufficiency on the pharmacokinetics of bleomycin has not been evaluated. However, hepatic toxicity, beginning as a deterioration in liver function tests, has been reported. These toxicities may occur at any time after initiation of therapy. Caution and monitoring is advised if bleomycin is used in patients with liver impairment.

References

  1. "Product Information. Blenoxane (bleomycin)." Bristol-Myers Squibb PROD (2001):

Blenoxane drug interactions

There are 259 drug interactions with Blenoxane (bleomycin).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer